GUAIFENESIN
(gwye-fen'e-sin)
Amonidrin, Anti-Tuss, Breonesin, Gee-Gee, GG-Cen, Glyceryl Guaiacolate, Glycotuss, Glytuss, Guaituss, Hytuss, Malotuss, Mytussin, Mucinex, Nortussin, Resyl , Robitussin
Classifications: antitussive; expectorant
Pregnancy Category: C

Availability

100 mg/5 mL syrup; 100 mg/5 mL, 200 mg/5 mL liquid; 200 mg capsules; 300 mg sustained release capsules; 100 mg, 200 mg, 1200 mg tablets; 600 mg sustained release tablets

Actions

Enhances reflex outflow of respiratory tract fluids by irritation of gastric mucosa.

Therapeutic Effects

Aids in expectoration by reducing adhesiveness and surface tension of secretions.

Uses

To combat dry, nonproductive cough associated with colds and bronchitis. A common ingredient in cough mixtures.

Contraindications

Hypersensitivity to guaifenesin; pregnancy (category C), lactation.

Route & Dosage

Cough
Adult: PO 200–400 mg q4h up to 2.4 g/d
Child: PO <2 y: 12 mg/kg/d in 6 divided doses; 2–5 y: 50–100 mg q4h up to 600 mg/d; 6–11 y, 100–200 mg q4h up to 1.2 g/d

Administration

Oral

Adverse Effects (1%)

GI: Low incidence of nausea. CNS: Drowsiness.

Diagnostic Test Interference

Guaifenesin may produce color interference with certain laboratory determinations of urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Interactions

Drug: By inhibiting platelet function, guaifenesin may increase risk of hemorrhage in patients receiving heparin therapy.

Pharmacokinetics

Not studied.

Nursing Implications

Assessment & Drug Effects

Patient & Family Education


Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug